TRCT
PBLA

Tower Research Capital (TRC)’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Tower Research Capital (TRC)’s Portfolio PBLA Stock Details PBLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-751
Closed -$13.7K – 6358
2023
Q4 		$13.7K Buy
751
+479
+176% +$7.5K ﹤0.01% 3941
2023
Q3 		$7.13K Buy
272
+86
+46% +$2.89K ﹤0.01% 4503
2023
Q2 		$8.54K Buy
+186
New +$37.7K ﹤0.01% 4420
2023
Q1 		– Sell
-1
Closed -$1K – 6790
2022
Q4 		$1K Hold
1
– – ﹤0.01% 5812
2022
Q3 		$4K Hold
1
– – ﹤0.01% 5352
2022
Q2 		$8K Buy
+1
New +$37K ﹤0.01% 4749
2022
Q1 		– Hold
0
– – – 5495
2021
Q4 		– Hold
0
– – – 4996
2021
Q3 		– Hold
0
– – – 4931
2021
Q2 		– Hold
0
– -$3K – 6161
2021
Q1 		– Hold
0
– – – 4969
2020
Q4 		– Hold
0
– – – 4283
2020
Q3 		– Hold
0
– – – 5247

Tower Research Capital (TRC)'s PBLA Position: Q1 2024 in Review

Tower Research Capital (TRC) sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q1 2024, closing a stake of 751 shares — an estimated $13.7K sold.

Tower Research Capital (TRC) first reported a position in PBLA in Q2 2022 and held it in 6 quarters. The position peaked at $13.7K in Q4 2023. 0 funds tracked by Wall St. Rank hold PBLA as of Q1 2024.

  • Tower Research Capital (TRC) reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 751 Panbela Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $13.7K.
  • Tower Research Capital (TRC) first reported a position in Panbela Therapeutics, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
  • Tower Research Capital (TRC)'s Panbela Therapeutics, Inc. Common Stock position peaked at $13.7K in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.